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1. Introduction 
The classical clonal evolution theory of neoplastic development supports the notion that 
cellular transformation results from random mutations and subsequent clonal selection. 
However, recent advancements in identification of the malignant populations responsible 
for tumor maintenance and recurrence have lent support to the cancer stem cell (CSC) 
hypothesis as a model of carcinogenesis, and posit that tumor growth is driven by a rare 
subpopulation of cells with stem cell-like properties. Cancer stem cells are commonly 
thought of as derivatives of a normal tissue stem cell that undergoes genetic alterations, 
which allow for sustained aggressive and clonal characteristics, self-renewal capacity and 
the ability to differentiate into all populations within a malignancy. Cancer stem cells alone, 
as compared to the bulk of cells in a tumor, are considered to be responsible for tumor 
initiation, metastasis and resistance to treatment. Moreover, CSCs are believed to share 
many properties with normal stem cells providing them with an overall insensitivity to 
conventional radio- and chemotherapy. Therefore, successful targeting of such a highly 
tumorigenic yet rare population must be considered in order to improve the therapeutic 
efficacy of the currently available anti-cancer therapy. Here, we provide a summary of 
recent progress towards development of biomarkers that identify CSCs, the molecular 
mechanisms behind the conventional anti-cancer therapy resistance, and the development of 
therapeutic strategies to selectively target CSC populations. 
2. Normal stem/progenitor cells and CSCs 
In the developing embryo, stem cells are located in the inner mass of the blastocyst where 
they are known as the embryonic stem cells and can give rise to the majority of cell types in 
the body, a characteristic referred to as pluripotency. At later developmental stages, 
embryonic stem cells differentiate into adult stem cells, which are multipotent (i.e., they can 
give rise to a restricted number of cell types) and form different tissues and organs (Fuchs 
and Segre 2000). One of the most important features of stem cells is their ability to undergo 
asymmetric cell division, a process whereby a progenitor cell gives rise to a new stem cell 
that can maintain its own progeny through self-renewal.  
CSCs reportedly share many properties with normal stem cells. It is still not clear whether 
CSCs derive from mutated tissue specific stem cells or more differentiated cells that have re-
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initiated a self-renewal program as part of or following transformation. Regardless of their 
origin, CSCs have been found to resemble the normal stem or progenitor cells of their 
tumor’s derivative tissue (Calabrese et al. 2007). Microscopic analysis of many malignancies 
reveals a complex heterogeneous picture composed of significant phenotypic diversity. 
Even though CSCs make up only a minor fraction of a tumor, they are defined by their 
ability to self-renew, producing tumorigenic daughter cells, and their ability to give rise to 
different nontumorigenic cancer cell phenotypes. Collectively, CSC-descendents contribute 
to the cellular heterogeneity of the tumor. 
3. Molecular signature for cancer stem cell 
Cancer stem cells are commonly characterized on the basis of the expression of specific- or 
combinations of molecules (e.g. CD133 and CD44), but they can also be distinguished from 
their progeny by functional attributes such as high expression of cytoprotective enzymes 
(e.g. aldehyde dehydrogenese, ALDH) and drug-efflux pumps (e.g. ABC transporters). 
Advancements in cell sorting technology via flow cytometry and fluorescent antibodies 
have enabled researchers to reproducibly isolate phenotypically defined rare cell 
populations. Utilizing these tools, John Dick’s laboratory first isolated CSCs from acute 
myeloid leukemia (AML) as early as 1997 (Bonnet and Dick 1997). In this pioneering work, 
Dick and colleagues showed that in human AML, a rare subset of tumor cells with the 
CD34+/CD38- signature possessed the ability to recapitulate the entire original disease over 
several transplantations. These findings suggest that self-renewal and pluripotency are 
characteristic of this small subpopulation, and are absent within the broader CD34+/CD38+ 
population (Lapidot et al. 1994; Bonnet and Dick 1997). The consensus view of 
hematological malignancies is that the CD34+/CD38- signature does not identify most CSCs 
(Alison et al., 2011). However, it should be noted that other markers have also been used to 
characterize CSCs in these cancers (Alison et al. 2011). In contrast, there is little agreement 
regarding the molecular identity of CSCs in solid tumors. The first solid tumor associated 
CSCs were isolated from breast cancer in 2003 (Al-Hajj et al. 2003). Since then, CSCs have 
been identified in brain- (Hemmati et al. 2003; Singh et al. 2003), colon- (O'Brien et al. 2007), 
melanoma- (Fang et al. 2005), pancreatic- (Hermann et al. 2007), prostate- (Collins et al. 
2005), ovarian (Bapat et al. 2005), lung- (Eramo et al. 2008) and gastric-cancers (Fukuda et al. 
2009). The isolation of many solid CSCs has been carried out using a number of adhesion 
markers including CD44 and CD24, or other CSC- associated functional markers such as 
multidrug efflux proteins ABC transporter and Prominin1 (CD133), an apical plasma 
membrane protein predominantly found on embryonal epithelial structures. In glioblastoma 
and medulloblastoma, CD133 is routinely used to enrich for CSCs (Singh et al. 2003). CD133 
expression has also been used as a CSC phenotypic marker for colon cancer (O'Brien et al. 
2007). However, although CD133 has continued to identify tumor cells with self-renewal 
capacity in a number of other solid tumors, there is an ongoing debate as to how robust a 
universal marker it actually is within the solid tumor CSCs (Wu and Wu 2009). Most of the 
cell surface markers used to distinguish stem cells in normal and cancerous tissues have 
thus far  not been expressed exclusively by stem cells alone. Additionally, the same markers 
used for isolation of CSCs in one organ cannot directly be used for identification in other 
organs. Such situations underlie the importance of combining phenotypic markers with 
functional markers as a signature to identify tissue specific CSCs.  
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4. Cancer stem cell and patient prognosis 
According to the CSC hypothesis, these cells are not only responsible for the unlimited 
growth of a tumor, but also for the maintenance of the minimal residual disease and 
constitutive recurrences following therapy and metastasis. Therefore, quantification of the 
presence of this rare population within a disease burden may serve as a prognostic 
indicator. Generally, it is believed that a high proportion of stem cells signify a worse 
prognosis. For example, in breast cancer, the most poorly differentiated tumors have the 
highest burden of CSCs (Pece et al. 2010). Similarly, elevated immunoreactivity of nestin and 
CD133 in tumor specimens is associated with a poor prognosis in patients with brain tumors 
(Laks et al. 2009). Furthermore, others have reported that high CD133 expression in brain 
tumors is a dismal prognostic marker for progression free- and overall-survival (Zhang et al. 
2008). Contrary to these findings, Kim and colleagues recently examined the three 
established stem cell markers, nestin, CD133 and CD15 in 88 cases of glioblastoma by 
immunohistochemical analysis and reported that there was no correlation between stem cell 
marker expression and the clinical outcome of these patients (Kim et al. 2011). Elevated 
expression of CD133 in colon cancer is also an independent marker of poor prognosis and is 
associated with liver metastasis (Horst et al. 2009). In pancreatic cancer, high CD133 
expression is an independent adverse prognostic factor for 5-years survival and is associated 
with lymph node metastasis (Maeda et al. 2008). Furthermore, the expression of the CSC 
specific functional markers, such as ALDH, is directly correlated with a poor prognosis in a 
number of tumors including AML (Cheung et al. 2007), breast (Morimoto et al. 2009), head 
and neck squamous cell carcinoma (Chen et al. 2009) and prostate cancer (Rasheed et al. 
2010). Another potential CSC associated marker is the ABC transporter, which has also been 
reported to be a sign of poor prognosis in AML patients, whereby there is a reduced overall 
4-year survival associated with elevated expression of ABCC11 (Guo et al. 2009). In 
summary, patients with tumors that express elevated levels of molecular markers related to 
CSCs tend to have a poorer prognosis than patients with tumors that express low levels of 
these makers. However, considering the inconsistency between individual stem cell 
markers, there is a need to define a CSC signature more precisely before it can be considered 
as a predictor of clinical outcome. 
5. Mechanisms of resistance and stem cell biology 
Like normal stem cells, CSCs are considered to be relatively quiescent. This characteristic 
leads to their relative resistance towards conventional radio- and chemotherapy, which 
predominantly targets rapidly dividing cells (Rich and Bao 2007). During therapy, the tumor 
burden may decrease significantly following treatment with the superficial appearance of 
tumor regression. However, quiescent CSCs can survive this therapy and eventually give 
rise to new daughter tumor cells and thereby re-initiate disease resulting in recurrence. In 
chronic myeloid leukemia (CML), a rare population of cells with the hematopoietic stem cell 
(HSC)-like phenotype harbor the definitive genetic aberration, t(9;22)(q34;q11) – the 
Philadelphia chromosome. This fusion product, a tyrosine kinase, is sufficient to initiate 
CML. Despite the immense success of Imatinib, a tyrosine kinase inhibitor, in controlling 
disease burden, a subpopulation of quiescent stem cells remains inherently resistant to 
therapy (Elrick et al. 2005). 
DNA damage repair pathways are considered to be the guardians of genomic and 
chromosomal stability. Because stem cells are at the basis of tissue homeostasis, they appear 
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to have a very efficient DNA repair capacity (Maynard et al. 2008). Moreover, it has been 
demonstrated that central nervous system (Smith et al. 2000) and hematopoietic stem cells 
contain lower levels of reactive oxygen species (ROS) as compared to their mature 
counterparts due to increased antioxidant defenses (Ito et al. 2004). In glioblastoma, 
increased DNA repair capacity in CD133+ CSCs appears to be related to the resistance to 
treatment (Bao et al. 2006). Other contributions to CSC radioresistance may arise from the 
fact that they may reside in hypoxic niches (Baumann et al. 2008). An increased expression 
of drug transporters, such as the ABC transporters, has been reported in many different 
types of normal stem cells (Zhou et al. 2001) and also in CSCs (Ginestier et al. 2007). Some 
studies suggest that the expression of such pumps on the cell surface represents a class of 
CSCs with high drug efflux capacity and an inherently increased resistance to 
chemotherapeutic agents (Hirschmann-Jax et al. 2004). Thus, it seems that CSCs may resist 
standard anti-cancer therapies via a combination of molecular mechanisms associated with 
normal stem cell biology. It is widely believed that in order to prevent relapse, effective 
targeting of CSCs is likely to be essential. 
6. Therapeutic strategies targeting cancer stem cells 
Most currently available cancer therapies are designed to target cells that are highly mitotic 
and rapidly dividing. However, nearly all malignancies are heterogeneous in nature. Many 
different types of cells have been shown to be present in tumors, including CSCs. These 
cells, which appear to provide the tumor initiating capacity in many cancers, are further 
capable of evading conventional chemo- and/or radiotherapy due to their inherent stem cell 
characteristics. After therapy, tumors have a higher population of therapy resistant stem 
cells; therefore specific targeting of this population is of utmost importance. Here, we 
highlight the latest strategies to successfully target and eliminate CSCs, the roots of cancer. 
6.1 Pharmacological targeting 
Small molecule inhibitors have shown promising results when used alone or in combination 
to target slow growing chemo- and radio-resistant CSCs. Several strategies have been 
employed including targeting signaling pathways that impart chemo- and radio-resistance 
to CSCs, thereby increasing their susceptibility to conventional therapy. Examples include 
targeting protective vascular niches that shield CSCs from environmental insults (Gilbertson 
and Rich 2007) and directly targeting apoptotic pathways, hence inducing programmed cell 
death in CSCs. 
In malignant brain tumor models, Bao et al. demonstrated that following conventional 
radiation therapy, a fraction of CD133+ brain tumor stem cells is enriched, which essentially 
contributes to the resistance of glioma through preferential activation of the DNA damage 
checkpoint response and to an increase in DNA repair capacity. Using specific 
pharmacological inhibitors of the Chk1 and Chk2 DNA checkpoint kinases, the 
radioresistance of CD133+ brain tumor stem cells can be reversed, making them susceptible 
to ionizing radiation (Bao et al. 2006). Reactive oxygen species (ROS), critical mediators of 
ionizing radiation-induced cell killing, are shown to be present at lower levels in some 
subsets of the CSC population in breast cancer. Lower ROS levels in CSCs are associated 
with an increased expression of free radical scavenging systems predisposing CSCs to 
develop less DNA damage and preferential sparing after irradiation. Pharmacological 
depletion of ROS scavengers in CSCs significantly decreases their clonogenicity and results 
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in radiosensitization (Diehn et al. 2009). Similarly, several pharmacological agents have 
shown promising results in the reversal of chemoresistance to the CSC population. In the 
setting of malignant glioma, the therapeutic efficacy of temozolomide (TMZ), an alkylating 
agent, on chemoresistant glioma stem cells was shown to be enhanced by Notch and SHH 
pathway inhibition with GSI-I and Cyclopamine (Ulasov et al. 2011). In CML, the 
combination of tyrosine kinase inhibitors (TKIs), i.e., imatinib, nilotinib, and/or dasatinib, 
with inhibitors of autophagy resulted in a near complete elimination of phenotypically and 
functionally defined CML stem cells (Bellodi et al. 2009). Pharmacological inhibition of 
Hedgehog (Hh) signaling, an essential stem cell maintenance pathway, has been found to 
impair not only the propagation of CML driven by wild type BCR-ABL1, but also the 
growth of imatinib-resistant CML in both mouse models and in humans (Zhao et al. 2009). 
BMS-214662, a cytotoxic farnesyltransferase inhibitor, alone or in combination with the 
tyrosine kinase inhibitors, imatinib mesylate and/or dasatinib, induces a selective apoptosis 
of proliferating and quiescent CML stem/progenitor cells while sparing normal 
stem/progenitor cells. BMS-214662 was also found to be cytotoxic even against CML blast 
crisis stem/progenitor cells, particularly in combination with a tyrosine kinase inhibitor and 
equally effective in cell lines harboring wild-type vs. mutant BCR-ABL (Copland et al. 2008).  
In AML, Zeng et al. demonstrated that SDF-1alpha/CXCR4 interactions contribute to the 
resistance of leukemic cells to signal transduction inhibitors and chemotherapy-induced 
apoptosis (Zeng et al. 2009). Therefore, it is not surprising that the disruption of these 
interactions with pharmacological inhibitors of CXCR4 is an effective strategy for sensitizing 
these leukemic stem cells to chemotherapy, thus targeting CSCs within the protective bone 
marrow microenvironment (Zeng et al. 2009). 
CSCs are situated in vascular niches or microenvironments that tightly regulate the supply 
of oxygen and nutrients to CSCs and thus control their self renewal and differentiation of 
CSCs (Gilbertson and Rich 2007).  In glioma xenograft models, the depletion of vascular 
endothelial cells by ERBB2 inhibitors (erythroblastic leukemia viral homolog 2, also known 
as human epidermal growth factor receptor 2) or VEGF signaling inhibitor has been shown 
to ablate self-renewing cells (Calabrese et al. 2007). Various small molecules have been 
shown to directly induce apoptosis in CSCs. In leukemia, TDZD-8 (4-benzyl, 2-methyl, 1,2,4-
thiadiazolidine, 3,5 dione) induces cell death by rapid loss of membrane integrity, depletion 
of free thiols and inhibition of both the PKC and FLT3 signaling pathways in phenotypically 
primitive cells, in vitro colony-forming progenitors, and leukemia stem cells, while sparing 
the physiology in the hematopoietic stem cell compartment (Guzman et al. 2007). The mTOR 
inhibitor rapamycin also effectively targets leukemia stem cells via modulation of the 
phosphoinositide 3-kinase/phosphatase and tensin homolog (PI3K/PTEN) pathway 
(Yilmaz et al. 2006). In AML, combinational treatment with the proteasome inhibitors 
carbobenzoxyl-l-leucyl-l-leucyl-l-leucinal (MG-132) and anthracycline idarubicin produces 
rapid and extensive apoptosis in the CSC population via inhibition of nuclear factor kappaB 
(NF-κB) and activation of p53-regulated genes, while leaving the normal hematopoietic stem 
cells viable (Guzman et al. 2007). In the setting of prostate cancer, inhibition of PI3K activity 
by the dual PI3K/mTOR inhibitor, NVP-BEZ235, inhibited the growth of CD133+/CD44+ 
prostate cancer progenitors (Dubrovska et al. 2009). Treatment with Lapatinib, an epidermal 
growth factor receptor [EGFR]/HER2 pathway inhibitor, in conjunction with conventional 
therapy, decreases the relative frequency of chemoresistant CD44+/CD24-/low breast cancer 
stem cells (Li and Ren 2008). In a phase III randomized trial for metastatic breast cancer 
using doxorubicin with or without N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine 
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(DPPE; tesmilifene), apoptosis was preferentially induced in CD44+/CD24-/low breast cancer 
stem cells. The increase in apoptosis attributed to the addition of the latter agent resulted in 
a significant improvement in the overall survival and a trend towards progression-free 
survival (Deng et al. 2009). 
Most of the anti-cancer drugs target proliferating tumor cells, which dramatically reduce 
tumor burden but to achieve durable cures may require successful elimination of CSCs that 
are proven to be responsible for tumor initiation, metastases and relapse. In the search for 
drugs that selectively target CSCs, we need to make sure that identified compounds do not 
affect normal stem cells with which CSCs share many properties. 
6.2 Immunotherapy 
Cancer stem cells (CSCs) have been associated with immunosuppressive properties (Di 
Tomaso et al. 2010), which are likely a critical part of the mechanism which endows the cells 
with tumor-promoting and immunomodulatory characteristics. CSC lines have also been 
shown to be deficient or expressing low levels of MHC-I, MHC-II, antigen processing 
machinery and NKG2D. Accordingly, recent work has demonstrated that the culture 
supernatant of adipose tissue stem cells isolated from breast cancer tissues upregulates the 
immunosuppressive cytokines (IL-10, TGF-β and induces conversion of conventional T cells 
into FoxP3-expressing regulatory T cells (Razmkhah et al. 2011), a potently 
immunosuppressive cell type of the adaptive immune system. Furthermore, CD200 has 
recently been recognized to be expressed by CSCs (Kawasaki et al. 2007). CD200-deficient 
mice exhibit gross autoimmune pathology when challenged in various models of 
experimental autoimmune encephalomyelitis and collagen-induced arthritis (Hoek et al. 
2000), implicating the important contribution of CD200 to normal tolerance and 
immunosuppression.  
Understanding the many different immunosuppressive pathways in CSCs allows for a more 
effective design of therapeutic elimination strategies. Among them, a combinatorial 
approach incorporating immunotherapy has been given serious consideration. One of the 
tenants of immunotherapy for CSCs is that while chemotherapy, surgical debulking and/or 
radiotherapy destroy the majority of cancer cells, the survival of small populations of cells 
with cancer-initiating potential persists, which can be targeted by the activated immune 
system. Accordingly, recent work has demonstrated that dendritic cells CSCs-fusion 
resulted in the activation of T cells expressing elevated levels of IFN-γ, with an enhanced 
killing-property against CSCs (Weng et al. 2010). In glioblastoma, CSCs growth and survival 
is supported by interleukin 6 (IL6) signaling based on data demonstrating that IL6 blockade 
contributes to CSC clearance (Wang et al. 2009). In patients with glioblastoma, elevated IL-6 
and its receptor expression are associated with reduced survival indicating potential clinical 
utility of the IL-6 signaling cascade as a target for therapy of primary tumors of the CNS 
(Wang et al. 2009). Glioma specific CSCs can also be targeted and killed by cytoloxic T 
lymphocytes (CTL) through a perforin-mediated mechanism. This is supported by recent 
work by Brown and colleagues demonstrating that CSCs derived from high-grade glioma 
may be recognized and eliminated by CD8+ CTLs (Brown et al. 2009). 
6.3 Genetic targeting 
6.3.1 miRNA 
Given that different types of cancer cells have a specific microRNA expression profile, 
utilization of microRNA-based therapeutic tools to target CSCs is being increasingly 
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exploited. The potential for CSCs self-renewal depends on a complex interplay of gene 
expression and environmental stimuli. Gene expression is controlled at different levels and 
can also be regulated by small micro-RNA molecules (miRNAs). miRNA are non-coding 
short nucleotide sequences (≈22 nucleotides in length) that block translation of transcripts 
with complementary mRNA sequences (Bartel 2004). Since miRNAs regulate differentiation 
and can function as tumor suppressors or oncogenes, the field of miRNA biology has 
become a subject of great interest for understanding stem cell self-renewal, 
immunosuppressor status and long lifespan. The number of miRNAs associated with cancer 
stem cells is continuously expanding. RNA interference strategies are at the frontline of 
targeting the aberrant expression of different genes utilizing miRNAs. Yu et al. (Yu et al. 
2007) using breast cancer stem cell were able to increase the expression of let-7 miRNA, 
accomplished via a lentiviral vector, leading to reduced proportion of stem cells and 
resulting in delayed tumor formation and metastasis. Similar results can be achieved not 
only in solid tumors, but also in leukemia. miRNA-17-92 was found to be up-regulated in 
leukemia stem cells (Jiang et al. 2010). However, targeting such CSC specific miRNA 
through RNA interference is yet to be tested in other major types of malignancies. 
6.3.2 Oncolytic virus 
Virotherapy, a therapeutic approach utilizing conditionally replicative viruses, may hold a 
potential to directly target self-renewing CSCs. In pre-clinical trials these viruses have 
demonstrated that these vectors function independent of common resistance pathways that 
exist for chemotherapeutic agents. Moreover, it is possible to construct viruses that would 
preferentially target cancer stem cells or other drug-resistant cells. Here, we summarize the 
recent efforts to develop oncolytic virus in order to target CSCs.  
Herpes simplex virus 
Attenuated herpes simplex virus (HSV) was used as one of the first gene therapy vectors to 
target glioma cells. To reduce neurotoxicity, HSV was deleted for RL1, which encodes the 
ICP34.5 and allows for virus replication even in the presence of the interferon (IFN) 
response. Later generations of the HSV construct restored the gene under the control of 
specific enhancers expressed in cancer cells. To preferentially target glioma stem cells that 
expressed high levels of nestin, the ICP34.5 was restored under the control of nestin, 
creating rQnestin34.5 (Kambara et al. 2005). Glioma stem cells shown to be resistant to 
conventional therapies were susceptible to the virus. Interestingly, IFNβ treatment inhibited 
viral replication only in neurospheres, known to be enriched of stem cells (Kurozumi et al. 
2008). This is important in light of the general view that cancer cells have a deficient 
interferon response and viruses such as VSV may not be able to target CSCs. 
Adenovirus   
Adenoviruses (Ad) are the most commonly used gene therapy vectors. After entry into the 
cell, the adenoviral early transcription region E1A binds with the cell cycle regulating 
protein retinoblastoma (Rb). Rb happens to be frequently mutated in various human 
cancers. Oncolytic adenoviruses were created by deleting a 24 nucleotide (Δ24)-specific 
region in E1A that binds Rb: as a result, the virus replicates only in cells that contain mutant 
Rb cells. Another approach has been to create adenoviruses that express E1A under the 
regulation of specific promoters found only in cancer cells. Since not all target cells express 
the necessary coxsackie-adenovirus receptor (CAR) to improve viral entry, adenoviruses 
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have undergone further surface modifications, such as replacing the fiber with serotype 3 
adenovirus (Ad5/3), or by adding polylysine (Ad.pk7) and RGD (Ad.RGD). Breast cancer 
stem cells were shown by Eriksson et al. to be successfully targeted by mutated Ads, Ad5/3-
Δ24 and Ad5.pk7-Δ24 (Eriksson et al. 2007). These viruses were able to kill not only 
CD44+/CD24-/low breast cancer stem cells, but also more differentiated cells. By using stem 
cell specific promoters, Cox-2, hTERT and mdr, Bauerschmitz et al. (Bauerschmitz et al. 
2008) from the same group was able to show a reduction in breast cancer stem cell 
population after treatment with Ad5/3-mdr-Δ24. Adenoviruses have shown similar efficacy 
in gliomas, esophageal and other CSC models. 
Reovirus 
Not all oncolytic viruses are affected by stem cell properties of cancer cells or target 
preferentially a sub-population within the tumor. Reovirus relies on abnormal activation of 
the Ras signaling pathway and Ras levels are equally upregulated in cancer stem cells and in 
the more differentiated populations (Marcato et al. 2009). As a result, Reovirus induces 
rapid oncolysis of colon-, breast-, lymphoma-, brain- and spinal-cancer cells without 
changing the cancer stem cell frequency. Since it causes a restriction of the cancer stem cell 
pool, it can also prove of benefit in prolonging remissions.  
The major benefit of gene targeting in cancer stem cells is the opportunity it offers in 
discovering new therapies. Although most of genetic approaches remain to be proven in 
clinical trials, they appear promising. Their safety profile and no cross-resistance with 
current therapies make them formidable candidates to combine with the conventional anti-
cancer therapy. 
7. Conclusion 
The identification of CSCs and the recent knowledge about the ability of CSCs to resist 
conventional chemo- and radiotherapy have prompted a number of novel targeting 
strategies to attack this rare but extremely important tumor subpopulation in order to 
eradicate cancer. Functional characterization of CSCs in disease progression and therapeutic 
resistance has altered our understanding of malignancy, which has led to a re-evaluation of 
conventional therapies for cancer. Although the jury is still out regarding the molecular 
signature used for the definitive isolation and characterization of the CSCs as well as 
defining the exact role that CSCs play in malignant disease progression, there is little doubt 
regarding the extraordinary capacity of CSCs to promote tumor growth, angiogenesis, 
invasion, therapeutic resistance and disease relapse post-therapy. These characteristics make 
CSCs a vital cell population that should be targeted effectively in order to develop 
successful anti-cancer therapy. Novel and effective therapies directed against CSCs may 
significantly improve the therapeutic efficacy of the currently available conventional 
therapies. Recent advancements in stem cell biology have allowed us to gain remarkable 
insight into the molecular mechanisms or signaling pathways that are differentially present 
in CSCs and non-stem cell tumor burdens. In this chapter, we have discussed several key 
molecular and signaling targets that have the potential to be utilized for future development 
of anti-CSC therapeutics. Most of these targets are still a long way from clinical application. 
However, the CSC paradigm has provided exciting new venues to improve cancer treatment 
by reducing recurrence and metastasis, which are considered to be the main cause of most 
cancer fatalities. 
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